Korean bio Loading... : Investor Sentiment and Bull/Bear Views

Loading chart...
Top Calls

No data yet

Price change since each call, adjusted for long/short direction. Results calculated:

Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
All Content
Source feeds
Buzzberg Top 50
All market capsNo capitalization filter
200 B and aboveMega
10 B to 200 BLarge
2 B to 10 BMid
0 to 2 BSmall
Custom
Enter market cap range in B USD
All directions
▲ Long
▼ Short
⛔ Avoid
✂ Close
◦ Others
Any score
LOW+
MED+
HIGH
? ?
03:19
Jan 20
Bio and Alteogen watch
Bio is a liquidity rotation beneficiary; Alteogen’s CEO said technology-transfer talks are numerous, and if a deal materializes it could lead the bio sector higher. JP Morgan healthcare deals usually lead to follow-through.
Korean bio
MED
03:19
Jan 20
Lee Ji-eun Representative of EasyStock 3PRO TV (삼프로TV)
Bio needs licensing trigger
Korean bio needs a technology-transfer trigger; Alteogen says many licensing talks are underway, and JP Morgan healthcare had many global deals but no Korean ones, so a successful Alteogen deal could reverse sentiment.
Korean bio
MED
03:34
Jan 16
Kwon Soon-woo Reporting Team Lead, 3PRO TV 3PRO TV (삼프로TV)
Korean exporters benefit from weak won
The Bank of Korea held rates at 2.5% because of high FX, inflation, and rising real estate, but weak won and tariff offsets are helping exporters. Autos, shipbuilding, power equipment, cosmetics, defense, nuclear, and bio are all showing strong exports even as domestic demand lags.
Korean bio
MED
03:34
Jan 16
Bio ETF improving but wait
Bio and healthcare fundamentals should improve with rate cuts, but the sector has been quiet after high expectations from the JPM healthcare conference and some licensing delays. It remains a watch-list ETF for 2026 rather than an immediate chase.
Korean bio
MED
23:28
Jan 15
Kwon Soon-woo Reporting Team Lead, 3PRO TV 3PRO TV (삼프로TV)
Korean bio exports hit record
Korean bio exports hit a record high, indicating strong global demand for Korean biotech products.
Korean bio
MED
03:33
Jan 06
Tiered allocation favors nuclear and defense
For balanced exposure, prioritize nuclear/defense/power equipment as first tier and bio/auto/robots as second tier, while keeping a semiconductor core and cash buffer.
Korean bio
MED

About Korean bio Investor Commentary

Across the available history and selected sources, Buzzberg tracks Korean bio across 1 sources: 3 bullish vs 0 bearish calls from 5 authors. Historical directional balance: 50% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 6 total trade ideas tracked. Latest voices: Jang Woo-jin, Lee Ji-eun, Kwon Soon-woo.